Related Experiment Video
Updated: Apr 28, 2026
09:29
Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder
Published on: January 9, 2015
18.6K
The serotonin paradox: Negative symptoms and SSRI augmentation
D Zullino1, G Bondolfi, P Baumann
1University Department of Adult Psychiatry, Biochemistry and Clinical Psychopharmacology Unit, Lausanne, Switzerland.
International Journal of Psychiatry in Clinical Practice
|June 20, 2014
Summary
Selective serotonin reuptake inhibitors (SSRIs) may improve negative symptoms in schizophrenia when added to antipsychotic medication. This suggests SSRIs could be an alternative treatment option for some patients.
Area of Science:
- Psychiatry
- Neuroscience
- Pharmacology
Background:
- Negative symptoms of schizophrenia are challenging to treat and impact long-term patient outcomes.
- Overlapping features between depressive and negative symptoms suggest potential therapeutic targets.
Purpose of the Study:
- To investigate the efficacy of augmenting antipsychotic treatment with antidepressants for negative symptoms in schizophrenia.
- To explore the direct effects of SSRIs on negative symptom improvement, independent of other symptom domains.
Main Methods:
- Review of studies examining the augmentation of neuroleptic (antipsychotic) medication with Selective Serotonin Reuptake Inhibitors (SSRIs).
- Analysis of correlations between SSRI-induced symptom improvement and changes in positive, depressive, or extrapyramidal motor symptoms.
Main Results:
- Evidence suggests SSRI augmentation enhances the efficacy of conventional antipsychotics in treating negative symptoms.
- Improvement in negative symptoms was not correlated with changes in positive, depressive, or extrapyramidal symptoms, indicating a direct effect.
Conclusions:
- SSRIs may offer a viable alternative to clozapine for managing negative symptoms in schizophrenia, particularly when clozapine is contraindicated.
- The mechanism by which both serotonergic (SSRIs) and antiserotonergic (atypical antipsychotics) agents improve negative symptoms requires further investigation.
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
1.3K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.3K
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
2.3K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
2.3K
01:25Antidepressant Drugs: Overview
2.1K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
2.1K
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
1.4K
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
1.4K
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
926
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
926
01:30Negative and Cognitive Symptoms of Schizophrenia
1.1K
Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
1.1K